Highlights
In a landmark randomized clinical trial involving men with nonmetastatic prostate cancer (PCa), the GnRH agonist leuprolide was associated with a significantly greater increase in total coronary plaque volume (TPV) over 12 months compared to the GnRH antagonist relugolix.
The observed increase in plaque volume was primarily driven by noncalcified plaque volume (NCPV), a specific phenotype of atherosclerosis often associated with higher vulnerability and increased risk of acute coronary syndromes.
